Cargando…
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
BACKGROUND: Rolapitant, a long-acting neurokinin (NK)(1) receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK(1) RAs, rolapitant does not inhibit or induce...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452074/ https://www.ncbi.nlm.nih.gov/pubmed/28327932 http://dx.doi.org/10.1093/annonc/mdx073 |